UniQure’s Glybera Is First Gene Therapy Okayed In Western Europe
This article was originally published in The Pink Sheet Daily
Executive Summary
UniQure’s Glybera (alipogene tiparvovec) has become the first gene therapy to be approved for commercialization in the 27-nation European Union, marking a major step towards making such medicines available for treating rare diseases that have a high unmet medical need.